Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino‐Kenudson, Kurt A. Schalper, Wendy A. Cooper, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 12, pp. 1335-1354
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Advances and challenges in the treatment of lung cancer
Yuting Li, Bingshuo Yan, Shiming He
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115891-115891
Open Access | Times Cited: 136
Pharmacogenomics: Driving Personalized Medicine
Wolfgang Sadée, Daqing Wang, Katherine E. Hartmann, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 4, pp. 789-814
Open Access | Times Cited: 84
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 4, pp. 705-710
Open Access | Times Cited: 49
Non-small-cell lung cancer
Lizza Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
New promises and challenges in the treatment of advanced non-small-cell lung cancer
May-Lucie Meyer, Bailey G Fitzgerald, Luís Paz-Ares, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 803-822
Closed Access | Times Cited: 38
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
Yue Zeng, Chunhong Hu, Yizheng Li, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1680-1688
Open Access | Times Cited: 23
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation
Lynette M. Sholl, Mark M. Awad, Upal Roy, et al.
Archives of Pathology & Laboratory Medicine (2024) Vol. 148, Iss. 7, pp. 757-774
Open Access | Times Cited: 17
Liquid biopsy for human cancer: cancer screening, monitoring, and treatment
Hao Wang, Yi Zhang, Hao Zhang, et al.
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 17
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Suying Yan, Wanting Wang, Zhiqiang Feng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma
Jie Peng, Dan Zou, Xudong Zhang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Jan Budczies, Eva Romanovsky, Martina Kirchner, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 9
Artificial intelligence‐driven change redefining radiology through interdisciplinary innovation
Runqiu Huang, Xiaolin Meng, Xiaoxuan Zhang, et al.
Deleted Journal (2025)
Open Access | Times Cited: 1
InterobServer AgreeMent in Pd‐l1 evaLuatIoN on cytoloGical samples—SAMPLING project: A multi‐institutional, international study
Gennaro Acanfora, Antonino Iaccarino, Bruna Cerbelli, et al.
Cancer Cytopathology (2025) Vol. 133, Iss. 3
Open Access | Times Cited: 1
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
R. J. Seager, Maria-Fernanda Senosain, Erik Van Roey, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Artificial Intelligence and Machine Learning in Predicting the Response to Immunotherapy in Non-small Cell Lung Carcinoma: A Systematic Review
Tanya Sinha, Aiman Khan, Manahil Awan, et al.
Cureus (2024)
Open Access | Times Cited: 6
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Elisa Bertoli, Elisa De Carlo, Debora Basile, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10803-10803
Open Access | Times Cited: 14
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
Sreya Duttagupta, Taiki Hakozaki, Bertrand Routy, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9406-9427
Open Access | Times Cited: 13
DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma
Shan Wei, Jing Xing, Jia Chen, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 5
PIM1/NF-κB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC
Xiuqiong Chen, Jing Zhou, Youhui Wang, et al.
Oncogene (2024) Vol. 43, Iss. 33, pp. 2517-2530
Closed Access | Times Cited: 5
Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance
Xiaolin Wu, Nuan Feng, Chao Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Jiexi Yan, Lu Yang, Qingmiao Ren, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer
Jiexiao Wang, Jialiang Wang, Xiang Huang, et al.
BMC Medical Imaging (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy
Shan-Shan Zhen, Wenqian Wang, Guohui Qin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Linoleic acid promotes TF expression through PPAR-α, which leads to tumor progression in primary pulmonary lymphoepithelioma-like carcinoma
Hejing Bao, Jiani Zhang, Zhuoyan Chen, et al.
Research Square (Research Square) (2025)
Closed Access
Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
Johnathan Arnon, Gal Dinstag, Omer Tirosh, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010132-e010132
Open Access
Page 1 - Next Page

Scroll to top